Merck and Moderna announce Phase III V940 trial for melanoma patients

Source: Clinical Trial Arena, July 2023

Merck (MSD) and Moderna are initiating a Phase III trial evaluating V940, an investigational individualised neoantigen therapy (INT), in combination with Keytruda, to treat patients with resected high-risk (Stage IIB-IV) melanoma.

Global recruitment has begun for the randomised Phase III trial V940-001 (NCT05933577). It is a randomised, double-blind, placebo and active-comparator-controlled study designed to evaluate the safety and efficacy of V940 (mRNA-4157) in combination with Keytruda (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with resected high-risk melanoma compared to Keytruda alone.

The trial will enrol approximately 1,089 patients at more than 165 sites across the globe. Patients will receive the intervention after complete resection.